FierceBiotech
@FierceBiotech
The dominant B2B news brand for biotech. Delivering news, revealing insights straight to your inbox.
加入 December 2008
615 正在關注 102.7K 粉絲
A phase 3 trial of Mirum Pharmaceuticals’ chronic hepatitis delta virus drug candidate has hit its primary endpoint, furthering the biotech’s efforts to enter a space recently colonized by Gilead Sciences.
顯示更多
